Recent blog posts
ANTXR1 Biologics Sequence Review Report 2026: Anthrax toxin receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ANTXR1 Biologics Sequence Review Report 2026: Anthrax toxin receptor 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ANTXR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ANXA2R Biologics Sequence Review Report 2026: Annexin-2 receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ANXA2R Biologics Sequence Review Report 2026: Annexin-2 receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ANXA2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
APLNR Biologics Sequence Review Report 2026: Apelin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
APLNR Biologics Sequence Review Report 2026: Apelin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of APLNR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ANKRD33 Biologics Sequence Review Report 2026: Photoreceptor ankyrin repeat protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ANKRD33 Biologics Sequence Review Report 2026: Photoreceptor ankyrin repeat protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ANKRD33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ALKAL1 Biologics Sequence Review Report 2026: ALK and LTK ligand 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ALKAL1 Biologics Sequence Review Report 2026: ALK and LTK ligand 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ALKAL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ALKAL2 Biologics Sequence Review Report 2026: ALK and LTK ligand 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ALKAL2 Biologics Sequence Review Report 2026: ALK and LTK ligand 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ALKAL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AMHR2 Biologics Sequence Review Report 2026: Anti-Muellerian hormone type-2 receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AMHR2 Biologics Sequence Review Report 2026: Anti-Muellerian hormone type-2 receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AMHR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AIRE Biologics Sequence Review Report 2026: Autoimmune regulator Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AIRE Biologics Sequence Review Report 2026: Autoimmune regulator Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AIRE protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AGTRAP Biologics Sequence Review Report 2026: Type-1 angiotensin II receptor-associated protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AGTRAP Biologics Sequence Review Report 2026: Type-1 angiotensin II receptor-associated protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGTRAP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AGTR2 Biologics Sequence Review Report 2026: Type-2 angiotensin II receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AGTR2 Biologics Sequence Review Report 2026: Type-2 angiotensin II receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGTR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ALCAM Biologics Sequence Review Report 2026: CD166 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ALCAM Biologics Sequence Review Report 2026: CD166 antigen Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ALCAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AGTR1 Biologics Sequence Review Report 2026: Type-1 angiotensin II receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AGTR1 Biologics Sequence Review Report 2026: Type-1 angiotensin II receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGTR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →